Drug Trial Radar · NCT04863274
Influence of Additional Physician's Consultations and Short Message Service (SMS) Reminders to Patient Compliance
Last checked: Nov 20, 2026Latest source record: May 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,912
Actual
Start
Jun 21, 2018
Primary completion
Oct 15, 2020
Study completion Oct 15, 2020
Sponsor
- Lead sponsor
- The League of Clinical Research, RussiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Research Center for Preventive Medicine
- First posted
- Apr 28, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A systematic collection of retrospective and prospective data based on non-interventional patient observation, aimed to assess the risks, course and outcomes of a disease or a group of diseases: * the retrospective part: database of patients with cardiovascular risks; * the prospective part: observation of patients in the real world medical practice.
Conditions
- Lipid Metabolism Disorders
Interventions
atorvastatinDrug
Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins. Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target level of LDL cholesterolTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
League of Clinical Research (LeagueCRR)
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.